Evidence map›Paper›PMID 28937091›Full record

ArticleCancer gene therapy2017

Obstruction of BRAF

J H Rothman, O Surriga, E de Stanchina, S D Vasudeva, G K Schwartz

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Localization ofCancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

J H RothmanHerbert Irving Comprehensive Cancer Center, Department of Medicine, Columbia University School of Medicine, New York, NY, USA.
O SurrigaHerbert Irving Comprehensive Cancer Center, Department of Medicine, Columbia University School of Medicine, New York, NY, USA.
E de StanchinaAntitumor Assessment Core Facility, Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S D VasudevaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
G K SchwartzHerbert Irving Comprehensive Cancer Center, Department of Medicine, Columbia University School of Medicine, New York, NY, USA.
Columbia University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Peptide nucleic acid (PNA) oligomers are DNA mimics, which are capable of binding gene sequences 1000-fold more avidly than complementary native DNA by strand invasion and effectively obstruct transcription. Irreversibly obstructing the transcription or replication of a gene sequence, such as BRAF

Indexed as

MelanomaMutation, MissenseProto-Oncogene Proteins B-rafAmino Acid SubstitutionAnimalsFemaleHumansMiceMice, NudePeptide Nucleic AcidsTranscription, GeneticXenograft Model Antitumor AssaysBRAF protein, humanPeptide Nucleic AcidsProto-Oncogene Proteins B-raf

Identifiers

PMID28937091
OpenAlexW2758489627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.